Azenta/$AZTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Azenta
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
Ticker
$AZTA
Sector
Primary listing
Employees
3,000
Headquarters
Website
Azenta Metrics
BasicAdvanced
$1.4B
-
-$2.41
1.62
-
Price and volume
Market cap
$1.4B
Beta
1.62
52-week high
$55.64
52-week low
$23.91
Average daily volume
588K
Financial strength
Current ratio
2.764
Quick ratio
1.97
Long term debt to equity
3.145
Total debt to equity
3.145
Profitability
EBITDA (TTM)
15.216
Gross margin (TTM)
42.13%
Net profit margin (TTM)
-16.68%
Operating margin (TTM)
-8.31%
Effective tax rate (TTM)
-4.77%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-1.60%
Return on equity (TTM)
-9.15%
Valuation
Price to revenue (TTM)
2.143
Price to book
0.85
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
27.156
Free cash flow yield (TTM)
3.68%
Free cash flow per share (TTM)
1.14
Growth
Revenue change (TTM)
12.46%
Earnings per share change (TTM)
-13.13%
3-year revenue growth (CAGR)
6.42%
10-year revenue growth (CAGR)
2.36%
3-year earnings per share growth (CAGR)
-56.39%
10-year earnings per share growth (CAGR)
36.16%
What the Analysts think about Azenta
Analyst ratings (Buy, Hold, Sell) for Azenta stock.
Bulls say / Bears say
Multiomics segment revenue increased 4% year-over-year (organic +3%), fueled by strong demand for next-generation sequencing services, confirming solid interest in Azenta’s genomic portfolio (PR Newswire)
Non-GAAP diluted EPS from continuing operations rose 31% to $0.19, and adjusted EBITDA margin expanded by 260 basis points to 12.3%, reflecting disciplined cost control and improved operational effectiveness (PR Newswire)
Azenta ended Q3 with $565 million in cash, cash equivalents, restricted cash and marketable securities, giving the company strong liquidity to support strategic initiatives and possible M&A activity (PR Newswire)
Sample Management Solutions revenue dropped 4% year-over-year, with organic revenue down 6%, highlighting ongoing challenges in Azenta’s core cold-chain sample management business (PR Newswire)
Total revenue held steady at $144 million year-over-year, with organic revenue decreasing 2%, demonstrating stagnant growth at the top line despite efforts to diversify segments (PR Newswire)
Total diluted EPS, including discontinued operations was $(1.15), impacted by a $50 million non-cash impairment related to B Medical Systems, underscoring persistent profitability challenges tied to divestiture efforts (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Azenta Financial Performance
Revenues and expenses
Azenta Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Azenta stock?
Azenta (AZTA) has a market cap of $1.4B as of October 21, 2025.
What is the P/E ratio for Azenta stock?
The price to earnings (P/E) ratio for Azenta (AZTA) stock is 0 as of October 21, 2025.
Does Azenta stock pay dividends?
No, Azenta (AZTA) stock does not pay dividends to its shareholders as of October 21, 2025.
When is the next Azenta dividend payment date?
Azenta (AZTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Azenta?
Azenta (AZTA) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.